CDKN2A and melanoma: Approximately 5-10% of melanomas have a strong familial link, and the molecular defects in most of these cases involve cell cycle regulators, particularly cyclin-dependent kinases (CDKs) and the CDK inhibitor p16 (CDKN2A) in their molecular pathogenesis [1-5].